Technology

Minerva Neurosciences

$3.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.74 (+27.31%) Today
+$0.06 (+1.74%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell NERV and other stocks, options, and ETFs commission-free!

About NERV

Minerva Neurosciences, Inc Common Stock, also called Minerva Neurosciences, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA. The listed name for NERV is Minerva Neurosciences, Inc Common Stock.

CEO
Rémy Henri Luthringer
Employees
13
Headquarters
Waltham, Massachusetts
Founded
2007
Market Cap
143.97M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
490.65K
High Today
$3.75
Low Today
$3.26
Open Price
$3.65
Volume
11.23M
52 Week High
$15.22
52 Week Low
$1.81

Collections

NERV Earnings

-$0.77
-$0.27
$0.23
$0.73
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 8, Pre-Market

You May Also Like

JJS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure